Seleziona una pagina

NEWS

01/05/2019 – ChemICare awarded funding from the European Union’s Horizon 2020 research and innovation programme (SME Instrument). 

PRESS REVIEW

PUBLICATIONS

  • Cordero-Sanchez C*, Riva B*, Reano S*, Clemente N, Zaggia I, Ruffinatti FA, Potenzieri A,
    Pirali T, Raffa S, Sangaletti S, Colombo MP, Bertoni A, Garibaldi M, Filigheddu N*,
    Genazzani AA*. A luminal EF-hand mutation in STIM1 in mice causes the clinical hallmarks
    of tubular aggregate myopathy. Disease Models & Mechanisms. 2019, 3; 13(2).
  • Riva B*, Griglio A*, Serafini M, Cordero-Sanchez C, Aprile S, Di Paola S, Gugliandolo E,
    Alansary, D, Biocotino I, Lim D, Grosa G, Galli U, Niemeyer B, Sorba G, Canonico PL,
    Cuzzocrea S, Genazzani AA, Pirali T. Pyrtriazoles, a Novel Class of Store-Operated Calcium
    Entry Modulators: Discovery, Biological Profiling, and in Vivo Proof-of-Concept Efficacy in
    Acute Pancreatitis. J. Med. Chem. 2018, 61, 9756−9783.
  • Garibaldi M, Fattori F, Riva B, Labasse C, Brochier G, Ottaviani P, Sacconi S, Vizzaccaro E,
    Laschena F, Romero N, Genazzani A, Bertini E, Antonini G. A novel gain-of-function
    mutation in ORAI1 causes late-onset Tubular Aggregate Myopathy and congenital miosis.
    Clin Genet, 2017, 91, 780-786.

VIDEO

10 + 12 =

ChemICare srl  – P:IVA 02505930038

Via Amico Canobio 4/6, Novara

info@chemicare.it

Informativa cookies